Blood Cell Preparation . PMN were obtained from peripheral blood as described (11) . Mononuclear cell fractions were washed in HBSS with 0.1% BSA (Sigma Chemical Co., St. Louis, MO) to remove platelets, and resuspended into RPMI with 0.1% BSA . Monocytes were isolated by two rounds of adhesion (30-60 min, 370C) to gelatin-coated tissue culture plastic (Costar) that had been exposed to autologous platelet-free plasma for 30 min at 37°C. Adherent cells were collected with EDTA (2-4 mM, 15 min, 370C). Lymphocyte-and monocyte-enriched fractions were also prepared by countercurrent flow elutriation (11) .
Adhesion Assays . Leukocytes were labeled with 2', 7'-bis-(-2-carboxyethyl)-5 (and -6) carboxyfluorescein, acetoxymethyl ester (BCECFAM ; Molecular Probes Inc., Eugene, OR) (2-5 mM, diluted from 1-M stock in DMSO; 20 min at 37'C) and resuspended in RPMI with 10% FCS . In some experiments, leukocytes were treated (20-30 min, 4°C) with heat-aggregated rabbit Ig (Pel-Freeze Biologicals, Rogers, AR; 10-20 mg/ml final concentration) to block potential Fc receptor interactions (1) . HEC were incubated with mAbs (100 til/well, culture supernatant or dilutions ofascites protein at 10 Wg/ml) for 30 min at 37'C before addition of0.5-2 x 10' leukocytes per well. mAbs were not routinely removed. After 30 min at 25'C, assay plates were inverted and centrifuged (1); the number of bound leukocytes was determined using an automated fluorescence concentration analyzer (Pandex Laboratories, Inc., Mundelein, IL). In certain experiments, leukocytes were treated with anti-CD11/CD18 mAbs (dilution of ascites, 1 :200 or 1 :500) at 4oC for 20-30 min before assay.
Flow Cytometry, RIA, and Immunostaining. For flow cytometry, 5 x 105 cells were exposed to primary mAbs (4oC, 30 min) followed by fluorescein-conjugated goat anti-mouse Ig (Boehringer Mannheim Biochemicals, Indianapolis, IN) (1 :50 dilution in HBSS with 0.1% BSA ; 4oC, 20 min), and fixed in I% paraformaldehyde in PBS . Cell surface RIAs were performed using "sI sheep anti-mouse Ig (New England Nuclear, Cambridge, MA) (1). For immunoperoxidase studies, cryostat sections of human tissues were exposed to mAbs (16 h at 4oC) and developed using aminoethylcarbazole or diaminobenzidine as chromagens .
Results and Discussion
Expression ofINCAM-110 In Vitro. Fewer than 10% of unstimulated HEC bound mAb El/6 by flow cytometric analysis, consistent with the low level expression previously observed by cell surface RIA (10) . mAb E1/6 bound to >80% of IL-1-or TNF treated HEC, with an increase in mean fluorescence intensity of N20-fold. mAb El/6 did not bind to blood mononuclear cells (lymphocytes and monocytes), PMN, or human dermal fibroblasts (AlF21 cells; RIA).
INCAM-110 and ICAM-1 Independently Mediate Lymphocyte Adhesion to Endothelial Monolayers. Exposure of HEC to IL-1 (5 U/ml, 6-8 h) increased the adhesion of PBL by 4.8 t 0.9 times (mean t SEM ; five experiments) . Anti-INCAM-110 mAb El/6 inhibited adhesion of PBL to IL-1-activated HEC by 41 t 5% (five experiments) (Fig. 1 ) . Treatment ofPBL with mAb El/6 (30 min, 4oC) followed by washing had no effect (data not shown). Anti-ICAM-1 mAb E1/7 also inhibited PBL adhesion to HEC, but to a lesser degree (12 t 3% ; four experiments) (6) . mAbs El/6 and El/7 in combination blocked PBL adhesion by 68 t 3%, while two irrelevant, isotype-matched mAbs (which bind to both control and cytokine-activated HEC) had no effect . Similar results were observed using anti-ICAM-1 mAb RRl/l (data not shown) .
mAb El/6 blocked the adhesion of Ramos cells (60 t 7 % ; four experiments) ( Fig.  1) , whereas anti-ICAM-1 mAb E1/7 had no effect (-1 t 5% inhibition) . In contrast, adhesion of an EBVtransformed B lymphoblastoid cell line (IB-4) was not substantially blocked by mAb El/6 alone (<10%), but was inhibited by mAb E1/7 (31 t 4% ; three experiments) . Greater inhibition was observed with a combination ofmAbs El/6 and E1/7 (55 t 6%) than with El/7 alone, suggesting a role for INCAM-110 in IB-4 adhesion . CEM cells (T lymphoblastic lymphoma) were more affected by mAb El/6 than by mAb E1/7 ( Fig. 1 ). These data suggest that INCAM-110 and ICAM-1 function independently to mediate lymphocyte adhesion . INCAM-110 Mediates Lymphocyte Adhesion by a CD111CD18-independent Mechanism. mAb TSI/22 (anti-CD11a) inhibited the adhesion of PBL to IL-1-activated HEC by 30 t 6% (mean f SEM; four experiments) ( Table I) . mAb E1/6 in combination with mAb TSl/22 resulted in greater inhibition of PBL adhesion (69 t 9% decrease ; four experiments) than either mAb alone. Similarly, the combination of (10) and ICAM-1 (3, 4) at low levels, mAbs El/6 and El/7 reduced the binding of isolated blood monocytes by 27 t 7% and 43 t 7%, respectively. On cytokine-activated HEC, mAb El/6 alone had little effect on the adhesion of monocytes (8 t 2% decrease ; 10 experiments) ; mAb E1/7 blocked adhesion by 17 t 3% (nine experiments) . Combinations of mAbs El/6 and E1/7 were more effective than either reagent alone (43 t 5% inhibition ; p <0 .001), further suggesting a role for INCAM-110 in monocyte adhesion . Similar results were observed with combinations of mAbs E1/6 and anti-CDlla (Table 1) . PMN adhesion to IL-1-activated HEC exhibited little or no dependence on INCAM-110. mAb El/6 alone did not block PMN adhesion (1 t 6% inhibition ; four experiments), nor did it further reduce the adhesion observed in the presence of blocking mAb against ICAM-1 or CD11/CD18 (data not shown) .
In Situ Expression ofINCAM-110 in Lymphoid Tissues andSites ofInflammation. Anti-INCAM-110 mAb E1/6 did not bind to endothelium of normal human skin (Fig .  2 A) (10) , but strongly reacted with small vessels (predominantly venules) associated with florid perivascular inflammatory infiltration in a delayed hypersensitivity reaction to tuberculin (72 h) (Fig . 2 B) . Similarly, mAb El/6 bound to vascular endothelium in a cutaneous insect bite reaction . mAb El/6 bound focally to venular endothelium in peripheral lymph node and tonsil (typically 5-20% of vessels), but did not to mark high endothelial venules selectively. mAb El/6 also bound to cells within lymphoid follicles (Fig. 2 C) and certain interfollicular cells (Fig . 2 D) having the appearance of follicular dendritic and interdigitating dendritic cells, respectively. INCAM-110 on dendritic cells could influence lymphocyte localization or antigen presentation, which may involve direct adhesive interactions (12) .
Increasing evidence suggests that activated vascular endothelium can affect the pattern and makeup of inflammatory cell infiltrates through expression of specific adhesion molecules (13) . ELAM-1 appears to function primarily in the adhesion of PMN (1, 2), while ICAM-1 appears to mediate adhesion of most leukocyte types (6) (7) (8) . The present studies indicate that INCAM-110 supports the adhesion of lymphocytes and monocytes, but not PMN. Expression of INCAM-110 on activated en- Photomicrographs of frozen sections of human tissues stained with an immunoperoxidase technique using mAb El/6 . Normal human skin (A) demonstrated little or no binding of mAb El/6, whereas the endothelial lining of vessels in a delayed-type hypersensitivity reaction (tuberculin) induced in the same patient (B) was strongly positive. In human tonsil (C), mAb El/6 reacted with vascular endothelium in a minority of small vessels . mAb El/6 also bound extensively to lymphoid follicles (C), primarily decorating cells ofdendritic morphology. Interfollicular cells with dendritic morphology were also marked (D). No significant reactivity was noted with control mAb K16/16 (IgGl) . dothelium in vitro is more sustained than that of ELAM-1, suggesting that it may act in concert with ICAM-1 in the development of chronic inflammatory processes. Summary Inducible cell adhesion molecule 110 (INCAM-110) is a 110-kD glycoprotein expressed on cytokine-activated human vascular endothelial cells. mAb blocking studies indicate that INCAM-110 and intercellular adhesion molecule 1 (ICAM-1) independently support the adhesion of lymphocytes to activated human umbilical vein endothelial cell monolayers. Anti-CDlla/CD18 antibodies with anti-INCAM-110 mAb E1/6 produce greater inhibition of lymphocyte adhesion than either reagent alone, suggesting that INCAM-110 and LFA-1 are not an obligate receptor-ligand pair. Blood monocytes, but not polymorphonuclear leukocytes, also appear to bind endothelial INCAM-110. Endothelial expression of INCAM-110 is upregulated at sites of inflammation, suggesting a role in the recruitment of mononuclear leukocytes.
